FOXP1 gene expression was significantly different between immunotherapy-responsive and immunotherapy-non-responsive groups of patients in the BeatAML (Figure 6A), TCGA AML (Figure 6B), and GSE6891 datasets (Figure 6C). This evidence concerns the gene FOXP1 and acute myeloid leukemia.